Vir Biotechnology, Gilead Strike Deal for Novel Tumor Treatments
Vir Biotechnology and Gilead collaborate on novel T-cell engagers for solid tumors in a deal worth up to $1.87 billion, plus royalties.
Stocks · News reference
Vir Biotechnology Receives FDA Fast Track Designation For VIR-5500 To Treat Metastatic Castration-Resistant Prostate Cancer
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to VIR-5500, a PSMA-targeted PRO-XTEN® dual-masked T-cell engager (TCE), for the
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Vir Biotechnology Signs Up To $1.875B Gilead Deal For 3 Cancer Drug Candidates; Gilead To Pay $65M Cash Upfront And Buy 1,765,486 Shares At $14.16 Each, For A Total Of $25M, Plus Up To $1.785B In Milestones And Royalties
Under the terms of the agreement, Vir Biotechnology will be responsible for discovery, design and optimization of three novel PRO-XTEN® dual-masked TCE development candidates targeting selected solid tumor-associated
8-K filing — Vir Biotechnology, Inc. (VIR)
Filed: 2026-10-14 AccNo: 0001628280-26-065826 Size: 244 KB Item 3.02: Unregistered Sales of Equity Securities Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Vir Biotechnology Announces Collaboration, License Agreement With Gilead To Discover, Engineer Three PRO-XTEN Dual-Masked T-Cell Engager Development Candidates Targeting Selected Solid Tumor-Associated Antigens
- Collaboration combines Vir Biotechnology’s T-cell engager discovery, AI-enabled protein engineering and clinically-validated PRO-XTEN® masking technology with Gilead’s oncology development and commercialization